RayzeBio is a clinical-stage radiopharmaceutical therapeutics company headquartered at 5505 Morehouse Drive, Suite 300, San Diego, California, and since 2024 a wholly owned Bristol Myers Squibb company. It develops targeted radiopharmaceutical therapies (RPTs) built on the alpha-emitting isotope actinium-225, led by RYZ101 (225Ac-DOTATATE) against somatostatin receptor 2 (SSTR2)-expressing tumors including gastroenteropancreatic neuroendocrine tumors, extensive-stage small cell lung cancer and hormone-receptor-positive breast cancer, alongside earlier programs targeting glypican-3 (GPC3) in hepatocellular carcinoma and ACP3, plus paired diagnostic imaging agents such as [68Ga]Ga-RAYZ-8009. Its public web presence is a WordPress corporate marketing site covering discovery capabilities, radioisotope manufacturing, the pipeline, posters and presentations, leadership and careers; the company operates no developer program and publishes no API, SDK, or machine-readable specification, and is profiled here for network completeness rather than for an API surface.
RayzeBio is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Oncology, and Radiopharmaceuticals.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
Show this score on your site.
It updates itself when the score changes. Paste this where you link to your API docs:
<a href="https://apis.io/providers/rayzebio/"><img src="https://apis.io/badge/rayzebio/card.svg" alt="RayzeBio on APIs.io — Kin Score by API Evangelist"></a>
Other styles, a README pill and a shields.io endpoint are on the badge page.
Raise your score.
Agent readiness — checks not met, largest first (exact, from this profile):
Machine-Readable Auth+10 pts — a served openid-configuration/oauth-authorization-server carrying `issuer` (served), else the securitySchemes class in the provider OpenAPIs — bound (mutualTLS, DPoP, Signature) > negotiable (oauth2 authorizationCode/clientCredentials, openIdConnect) > bearer (http bearer, apiKey)
Idempotency+9 pts — OpenAPI mutating operations declare an idempotency key — a header, a request-body property, or a named de-duplication token whose own description says so (verified); else common[].type matches /idempoten/i (documented)
Stable Error Semantics+8 pts — OpenAPI $refs a shared error schema across 4xx/5xx responses (verified), else common[].type includes ErrorCatalog / ErrorCodes / DeclineCodes
13 more unmet checks in the Agent Readiness table above.
Kin Score — facets with the most composite points still available (weight × headroom):
aid: rayzebio
name: RayzeBio
description: RayzeBio is a clinical-stage radiopharmaceutical therapeutics company headquartered at 5505 Morehouse Drive,
Suite 300, San Diego, California, and since 2024 a wholly owned Bristol Myers Squibb company. It develops targeted radiopharmaceutical
therapies (RPTs) built on the alpha-emitting isotope actinium-225, led by RYZ101 (225Ac-DOTATATE) against somatostatin receptor
2 (SSTR2)-expressing tumors including gastroenteropancreatic neuroendocrine tumors, extensive-stage small cell lung cancer
and hormone-receptor-positive breast cancer, alongside earlier programs targeting glypican-3 (GPC3) in hepatocellular carcinoma
and ACP3, plus paired diagnostic imaging agents such as [68Ga]Ga-RAYZ-8009. Its public web presence is a WordPress corporate
marketing site covering discovery capabilities, radioisotope manufacturing, the pipeline, posters and presentations, leadership
and careers; the company operates no developer program and publishes no API, SDK, or machine-readable specification, and
is profiled here for network completeness rather than for an API surface.
url: https://raw.githubusercontent.com/api-evangelist/rayzebio/refs/heads/main/apis.yml
deliveryModel:
model: saas
open_source: false
commercial: true
callable_host: false
label: Hosted service · you call their endpoint
confidence: medium
source:
- pricing
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
probe_state: none
source:
- security
generated: '2026-11-06'
method: derived
image: https://rayzebio.com/wp-content/uploads/2024/04/rayzebio_logo_grt_gry-300x122.png
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-26'
modified: '2026-08-26'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Oncology
- Radiopharmaceuticals
- Life Sciences
- Healthcare
- Clinical Trials
- Drug Discovery
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: DomainSecurity
url: security/rayzebio-domain-security.yml
- type: Website
url: https://rayzebio.com/
- type: About
url: https://rayzebio.com/about/about-overview/
- type: Team
url: https://rayzebio.com/about/team/
- type: Contact
url: https://rayzebio.com/contact/
- type: Careers
url: https://rayzebio.com/careers/
- type: BlogRSS
url: https://rayzebio.com/feed/
- type: PrivacyPolicy
url: https://rayzebio.com/privacy-policy/
- type: TermsOfService
url: https://rayzebio.com/terms-of-use/
- type: LinkedIn
url: https://www.linkedin.com/company/rayzebio/
- type: ParentCompany
url: https://www.bms.com/
- type: SecondaryMarketListing
url: https://forgeglobal.com/rayzebio_stock/
x-enrichment:
date: '2026-08-26'
status: minimal
artifacts_added: 2
pass: local-v1
x-coverage:
state: none
reason: not-a-software-company
detail: 'RayzeBio is a clinical-stage radiopharmaceutical drug developer, now a Bristol Myers Squibb company, whose entire
public surface is a 25-page WordPress marketing site — /openapi.json, /openapi.yaml, /swagger.json, /api-docs, /graphql,
/llms.txt and every /.well-known/* path return a real 404, no GitHub org or npm/PyPI package exists under the name, and
the only machine-readable endpoint on the host is the default WordPress /wp-json/ CMS route index (209 core/plugin routes:
wp/v2, yoast, akismet, contact-form-7, wpe cache), which is WordPress plumbing and not a RayzeBio API product.'
evidence:
- url: https://rayzebio.com/openapi.json
status: 404
- url: https://rayzebio.com/graphql
status: 404
- url: https://rayzebio.com/.well-known/agent-card.json
status: 404
- url: https://rayzebio.com/llms.txt
status: 404
- url: https://rayzebio.com/wp-json/
status: 200
- url: https://api.github.com/orgs/rayzebio
status: 404
- url: https://rayzebio.com/media/news-new/
status: 301
checked: '2026-08-26'
Calls without X-API-Key need no key. Calls with it need a paid plan — get a key.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.